ORYZON Announces a New Financing Through a Convertible Bond Program For a Total Amount of Up To €45 Million
November 21, 2023 12:19 ET
|
Oryzon Genomics, S.A.
Funding provided by Nice & Green SA, a Swiss private investor This CB Program supersedes the previous oneTo extend its cash runway and continue the ongoing clinical trials in CNS and oncology...
ORYZON Announces Last Patient Last Visit in its Phase IIb PORTICO Study for Borderline Personality Disorder (BPD)
November 07, 2023 08:00 ET
|
Oryzon Genomics, S.A.
Company on track to report top line data milestone in 1Q 2024A total of 210 participants have been recruitedMultiple primary endpoints include reduction in agitation and aggression and overall BPD...
ORYZON to Provide Corporate Progress Updates at Several Events in November
November 06, 2023 08:00 ET
|
Oryzon Genomics, S.A.
BIO-Europe 2023LSX Investival Showcase 2023Jefferies London Healthcare Conference 2023 MADRID, Spain and BOSTON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015,...
ORYZON Reports Financial Results and Corporate Updates for Quarter Ended September 30, 2023
October 27, 2023 12:12 ET
|
Oryzon Genomics, S.A.
Positive aggregate safety data from vafidemstat's fully enrolled PORTICO Phase IIb trial in Borderline Personality Disorder (BPD), consistent with safety data from seven completed clinical trials,...
ORYZON presents blinded aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder
October 10, 2023 08:00 ET
|
Oryzon Genomics, S.A.
At the 36th European College of Neuropsychopharmacology congress (ECNP-2023) MADRID, Spain and BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a...
ORYZON Receives Two Grants to Further Explore the Role of Epigenetic Targets in the Treatment of Neuronal Pathologies
October 03, 2023 08:00 ET
|
Oryzon Genomics, S.A.
Two collaborative projects with public research centers with a global budget of 2.3 million eurosOryzon to receive up to 1.4 million eurosFocused on the discovery and validation of novel biomarkers...
ORYZON to Provide Corporate Progress Updates at Several Events in October
October 02, 2023 08:00 ET
|
Oryzon Genomics, S.A.
East-West Biopharma Summit 36th European College of Neuropsychopharmacology congress (ECNP 2023)Investor Access 2023 EventJefferies Inaugural Biotech CNS/Neuro Summit Roth Capital Partners 2nd...
ORYZON to Give Updates on Corporate Progress in September
September 05, 2023 08:00 ET
|
Oryzon Genomics, S.A.
H.C. Wainwright Global Investment Conference in NYCSachs Annual Biotech in Europe Forum in BaselThird Annual Global CMT Research Convention in BostonBioSpain-2023 in Barcelona MADRID, Spain and...
Oryzon Announces Completed Patient Recruitment in the PORTICO Phase IIb Trial of vafidemstat in Borderline Personality Disorder
July 26, 2023 08:00 ET
|
Oryzon Genomics, S.A.
Full recruitment secures the target number of completer patientsMultiple primary endpoints include reduction in agitation and aggression and overall disease improvementTopline efficacy data expected...
ORYZON Reports Financial Results and Corporate Updates for Half-Year Ending June 30, 2023
July 24, 2023 12:47 ET
|
Oryzon Genomics, S.A.
Positive aggregate safety data from vafidemstat's PORTICO Phase IIb trial in Borderline Personality Disorder (BPD), consistent with safety data from seven completed clinical trials, supporting the...